Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling (Q39179377)

9 September 2017

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling (English)

1 reference

9 September 2017

1 reference

1

1 reference

9 September 2017

2

0 references

Vitaliy O. Kaminskyy

4

0 references

Mattias Carlsten

3

0 references

Andreas Lundqvist

8

0 references

Boris Zhivotovsky

6

0 references

author name string

Padraig D'Arcy

5

1 reference

PubMed ID

23504627

9 September 2017

Richard Childs

7

1 reference

PubMed ID

23504627

9 September 2017

language of work or name

English

0 references

publication date

11 April 2013

1 reference

International Journal of Cancer

9 September 2017

1 reference

9 September 2017

133

1 reference

9 September 2017

1643-1652

1 reference

9 September 2017

7

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

9 September 2017

1 reference

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells

21 January 2018

1 reference

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

21 January 2018

1 reference

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

21 January 2018

1 reference

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

21 January 2018

1 reference

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

21 January 2018

1 reference

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

21 January 2018

1 reference

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

21 January 2018

1 reference

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

21 January 2018

1 reference

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells

21 January 2018

1 reference

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression

21 January 2018

1 reference

Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

21 January 2018

1 reference

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

21 January 2018

1 reference

Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity

21 January 2018

1 reference

TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis

21 January 2018

1 reference

Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response

21 January 2018

1 reference

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

21 January 2018

1 reference

Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells

21 January 2018

1 reference

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells

21 January 2018

1 reference

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

21 January 2018

1 reference

2B4 inhibits NK-cell fratricide

21 January 2018

1 reference

Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

21 January 2018

1 reference

Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins

21 January 2018

1 reference

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

21 January 2018

1 reference

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

21 January 2018

1 reference

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

21 January 2018

1 reference

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28163

1 reference

9 September 2017

1 reference

PubMed ID

23504627